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Abstract
Type 2 diabetes is associated with an increased risk of heart failure. Left ventricular diastolic
dysfunction and type 2 diabetes are frequently associated. Using echocardiography, we
know that tissue Doppler imaging E/e’ ratio is a reliable predictor of left ventricular filling
pressure. We performed a systematic review and meta-analysis to investigate the averaged
E/e’ ratio value in patients with type 2 diabetes compared to non-diabetic controls. In the
analysis we included cross-sectional studies providing the averaged E/e’ ratio. Subgroup/
sensitivity analyses were conducted according to variables known to influence E/e’ ratio
measurements. The analysis included 15 cross sectional studies with 877 type 2 diabetes
patients and 1193 controls. The weighted mean difference showed higher values in diabetes
(WMD 2.02; 95% CI 1.35, 2.70; p<0.001). The result was consistent in the subgroup/sensi-
tivity analyses. Visual inspection of the funnel plot did not identify substantial asymmetry
and the Egger test for funnel plot asymmetry showed a p value of 0.36. In conclusion, our
assessment suggests that averaged E/e’ ratio is consistently increased in patients with type
2 diabetes compared to non-diabetic controls in the absence of cardiovascular diseases
and complicated hypertension. This alteration may be a precocious diastolic alteration in the
diabetic cardiomyopathy.
Introduction
Diastolic dysfunction is an important cause of heart failure (HF) with preserved ejection frac-
tion (pEF) in diabetes, overall in type 2 diabetes [1]. Considering the worldwide epidemic
increase in type 2 diabetes incidence along with complications [2], it is presumable that this
cardiac condition will become a major public health burden [3]. Epidemiologic studies have
shown that different grades of diastolic dysfunction may be detected in patients with type 2
diabetes [4–6].
Left ventricular (LV) end-diastolic pressure (LVEDP) or pulmonary capillary wedge pres-
sure (PCWP) are frequent measures used to assess LV diastolic function [7]. In this respect,
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echocardiography is the mainstay for the noninvasive evaluation of diastolic function [7].
Early mitral annular velocity (e’) obtained by tissue doppler imaging estimates LV myocardial
relaxation activity: e’ less than 10 (lateral annular location) and e’ less than 7 cm/sec (septal
annular location) may suggest impaired myocardial relaxation [7].
With mitral early filling velocity E, the ratio E/e’ is largely used to estimate the left ventricu-
lar filling pressure (LVFP) and its use is recommended by the echocardiographic Societies to
evaluate diastolic function and HFpEF [7–8].
Despite a large use of E/e’ ratio, the extent of its alteration in type 2 diabetes without cardio-
vascular complications is still elusive.
In the present meta-analysis we summarize the averaged E/e’ ratio mean difference between
subjects affected by type2 diabetes without cardiovascular complications and control subjects.
We also summarize the averaged E/e’ ratio mean difference in various clinical conditions in
patients with type 2 diabetes that may confound this relationship.
Materials and methods
We conducted this systematic review and meta-analysis in accordance with the PRISMA
guidelines [9] and registered our project with the international prospective register of system-
atic reviews (PROSPERO—number CRD42018093585)
Search strategy
Four investigators (G.Z., A.M., M.D., G.T.) independently searched PubMed, Web of Science
and Scopus for pertinent articles. Furthermore, the investigators scanned references of
retrieved articles and pertinent reviews to detect further studies.
As reported in Fig 1, we performed two kinds of researches: 1) more liberal using generic
items (‘Diabetes’, ‘Diastolic dysfunction’, ‘Controls’) and (‘Diabetes’, ‘Tissue doppler’, ‘Con-
trols’) that retrieved 760 studies; 2) using more restrictive items: (‘Diabetes’, ‘Tissue Doppler
velocity’, ‘Controls’) and (‘Diabetes’, ‘e/e’, ‘Controls’) that retrieved 32 studies.
The PubMed search was carried out by using isolated terms, not phrases nor Boolean oper-
ators in order to retrieved the larger number of references (free word searching). The terms
were written directly in the search mask. Limits: only articles published in English were con-
sidered, we only included studies reporting data obtained by transthoracic echocardiography.
Duplicates were manually searched. The last search update was on January 20, 2018.
Eligibility criteria and identification of study
Definition and diagnosis of diabetes has been the same since 2010 [10]. Studies were included
if they provided the mean E/e’ ratio (averaged TDI e’ values of lateral and septal annular
region), comparing values in type 2 diabetes patients and in control subjects. Inclusion criteria
were cross-sectional studies reporting the mean E/e’ ratio in adult patients with type 2 diabetes
without any previous cardiovascular diseases except non complicated hypertension and
matched or unmatched controls subjects. Exclusion criteria were studies reporting either sep-
tal or lateral annular e’ measures, studies on those under 18 years and studies on subjects with
known cardiovascular diseases, including atrial fibrillation.
Study selection and data extraction
The four authors reviewed the findings of the electronic search and selected the articles poten-
tially relevant to the topic of interest. The identified articles were downloaded and then
assessed against the eligibility criteria. Any discrepancy in an author’s opinion on the inclusion
E/e’ ratio in patients with diabetes vs controls
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of an article was resolved by consensus and/or by involving the other authors (C.B., A.R., E.
B.). Two reviewers (G.Z., M.D.) independently extracted the data from each study, which were
recorded into a pre-defined collection sheet. Data extracted from each study included the
number of type 2 diabetes patients and controls, the mean of averaged E/e’ ratio of both groups
and the standard deviations of both groups along with other data (Table 1).
Quality assessment of study design
Methodological quality of selected cross-sectional studies was estimated using the Newcastle-
Ottawa scale (NOS). The NOS explores risk of bias in three different domains: selection, com-
parability and outcome/exposure. A maximum cumulative score of 9 (stars) points can be
obtained: four stars for selection, two stars for comparability and three stars for outcome/expo-
sure. Studies were classified as high-risk (1–3 points), intermediate (4–5 points) or low-risk of
bias (6–9 points) [11]. Three authors made the NOS score independently and a final agreement
was reached (S2 Table). The authors’judgments about each domain of the Newcastle-Ottawa
Scale is presented in S3 Table, while the Cochrane Risk of Bias Study-by-Study in S4 Table.
Fig 1. The PRISMA flowchart of the systematic search and quantitative synthesis.
https://doi.org/10.1371/journal.pone.0209794.g001
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Analysis
The analysis investigated the differences between averaged E/e’ ratio between patients with
type 2 diabetes and non-diabetic controls. We further conducted a subgroup/sensitivity analy-
ses to explore the possible sources of heterogeneity.
Statistical analysis
Mean values and standard deviation (SD) of the variables of interest were collected for the
analysis. If data were reported only as median and interquartile range (none of the final studies
included), published and online Cochrane’s recommendations to approximate the values of
mean and SD can be followed [12]. One study reported the geometric mean, however as the
measure of interest was the difference of the means, we included this difference measure in the
analysis.
The weighted mean differences (WMDs) were used to compare the averaged E/e’ ratio
between the case and control subjects. The pooled data were calculated by using a random-
effect model to achieve a more conservative assessment. Statistical heterogeneity was estimated
using Cochrane’s Q test and the I2 statistics. Heterogeneity was likely if Q>df (degree of free-
dom), and confirmed if P� 0.10. Quantification of heterogeneity was performed by using I2
statistics. The degree of heterogeneity was defined as none, low, moderate or high according to
I2 values of 0–24.9%, 25–49.9%, 50–74.9% and> 75%, respectively. Publication bias was quali-
tatively assessed by the visual inspection of funnel plot asymmetry of the MD against their
standard errors. The Egger’s regression asymmetry was also calculated and a P<0.05 was con-
sidered to be suggestive of a statistically significant publication bias. Meta-analysis was per-
formed with R metaphor.
This study was conducted in compliance with the Cochrane Collaboration and the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [13–14]. A p
value less than 0.05 was considered as statistically significant.
Table 1. Characteristics of enrolled case-control studies of averaged E/e’ ratio in type 2 diabetes patients compared to non-diabetic controls. OP: outpatient; CP:
consecutive patient; H: healthy control. NOS: Newcastle-Ottawa scale. Case: type 2 diabetic patients; Control: healthy non-diabetic controls.
Case Control
Study Country Source n Age yrs Sex M/F E/e’ Source n Age yrs Sex M/F E/e’ Matching NOS score Hypertension HbA1c
Tayebjee MN UK OP 54.00 68±5 43/12 10.9±1.3 H 31.00 66±5 18/13 8.1±2 age and sex 6 1 7.3
Govind SC. Sweden CP 31.00 49.2±6.3 20/11 10.8±2.4 H 13.00 49.7±5.4 8/5 7.9±0.7 age. LV size and ECG
parameters
6 0 8.1
Yazici M. Turkey OP 72.00 49.1±9.8 36/36 6.2±3.8 H 50.00 46.1±9.8 17/33 6.2±2.8 no 6 0 8.3
Mogelvang R. Denmark OP 65.00 68±11 42/13 12.7±1.5 NA 533.00 51±14 233/300 9±1.3 no 6 0
Andersson CH. Denmark OP 31.00 58±12 16/15 9.9±5.8 H 31.00 58±12 16/15 7.0±1.6 age.sex.hypertension 8 1
Tayyareci Y. Turkey CP 60.00 58.2±11.3 21/39 8±1.6 H 40.00 57.4±8.1 12/28 4.8±1.4 age and sex 7 0 7.6
Ernande L. France OP 114.00 52±4.5 60/45 10.9±3.6 H 88.00 51.7±2.6 30/58 7.7±1.7 age and sex 7 1 7.7
Ceyhan K. Turkey CP 48.00 56±11 28/20 11.5±3.0 H 60.00 56±11 32/28 9.8±2.2 age and sex 7 0 7.8
c¸iftel S. Turkey CP 21.00 54.1±5.7 11/10 4.9±1.9 H 40.00 53±6.8 17/23 5.6±1.9 no 5 0 9.4
Conte L. Italy OP 44.00 60.9±6.6 23/21 9.3±3.4 H 24.00 58.4±9.4 13/11 7±1.6 no 4 1 7.3
Erdogan D. Turkey NA 45.00 51.6±7.2 19/26 10.25±3.11 NA 43.00 50.4±8.5 18/25 9.05±2.41 no 5 1 7.4
Atas J. Turkey CP 40.00 50.5±7.3 7.7±2.3 H 40.00 48.4±6.7 6.2±1.3 age and sex 7 0 7.3
Bakirci EM. Turkey CP 132.00 54.5±9.6 76/56 8.9±2.8 H 80.00 53.2±9.0 50/30 8.6±2.5 age and sex 7 0 8.4
Loncarevic B Serbia CP 70.00 54.8±7.7 38/32 10.11±3.27 H 80.00 54.8±4.9 44/36 7.40±1.42 age and sex 6 0 6.7
Vukomovic V. Serbia CP 50.00 55±7 26/24 9.4±3 H 40.00 50±9 12/18 7.0±1.8 no 5 0 7.3
https://doi.org/10.1371/journal.pone.0209794.t001
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Results
The literature search produced 32 titles for the restrictive search strategy and 760 for the more
liberal search approach. No additional articles were found by an independent search. All arti-
cles were screened yielding 40 studies as potentially relevant and full-text was retrieved.
Twenty four studies were excluded: thus the sixteen remaining papers were selected for the
qualitative synthesis, while fifteen were selected for the quantitative synthesis. The search on
Embase and Scopus did not add further evidence to the Medline findings.
Therefore, 15 studies included in the meta-analysis provided transthoracic echocardio-
graphic data on TDI values, in particular they provided results on averaged E/e’ ratio.
The PRISMA flowchart of our systematic search and quantitative synthesis is reported in
Fig 1. The characteristics of the studies included are summarized in Table 1 [15–29].
Fifteen cross sectional observational studies provided values of the averaged E/e’ ratio
between patients with type 2 diabetes (n = 877) and non-diabetic controls (n = 1193). The
WMDs forest plot of this analysis is shown in Fig 2. Overall, type 2 diabetes patients without
Fig 2. The Forest plot of the weighted mean difference (WMD) of E/e’ ratio with 95% C.I. of the included studies that compared averaged E/e’ between
patients with and without diabetes. A positive value signifies that E/e’ is higher in patients with diabetes.
https://doi.org/10.1371/journal.pone.0209794.g002
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cardiovascular diseases exhibited a significantly higher averaged E/e’ ratio (WMD 2.02; 95%
CI 1.35, 2.70; p<0.001, Fig 2) with high heterogeneity (I2 = 89.9%; p< 0.001). Considering the
significant heterogeneity among the studies, we conducted subgroups/sensitivity analyses. The
region, the selection of controls (matching vs not matching), presence of non-complicated
hypertension, and glycemic control (HbA1c� 7.3% vs HbA1c > 7.3%) may have influenced
the summary combination, therefore we performed subgroups analyses according to these fac-
tors. The weighted forest plots of these analyses are shown in Fig 3. According to the region,
Fig 3. The Forest plot of the WMD with 95% C.I. of the subgroup analyses: Panel A, region; panel B, matching;
panel C, hypertension; panel D, glycemic control. A positive value signifies that E/e’ is higher in patients with
diabetes.
https://doi.org/10.1371/journal.pone.0209794.g003
E/e’ ratio in patients with diabetes vs controls
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the studies were divided in two subgroups and higher heterogeneity was found in studies from
Serbia and Turkey (I2 = 88.5%; p< 0.001). The overall WMD was 3.12 (95% CI 2.65, 3.59) in
the west European region and 1.40 (95% CI 0.53, 2.16) in Serbia and Turkey region. High het-
erogeneity was found independently of controls matching. The not matching subgroup pre-
sented I2 = 92.7% (p< 0.001) while the matching subgroup had I2 = 83.0% (p< 0.001). The
presence of non-complicated hypertension was associated with a lower heterogeneity (I2 =
56.2%; p = 0.072) compared to the absence of hypertension (I2 = 93.2%; p< 0.001). Moreover,
the WMD was 2.52 (95% CI 1.79, 3.24) when non-complicated hypertension was present and
1.81 (95% CI 0.88, 2.73) in the absence of hypertension.
Substantial low heterogeneity was found in the subgroup of studies with low mean HbA1c
(� 7.3%) with I2 = 39.7% (p< 0.177) respect to the studies with higher mean HbA1c (> 7.3%)
with I2 = 91.8% (p< 0.001). The HbA1c was chosen because it was the median value of the
means. The WMD was 2.34 (95% CI 1.82, 2.85) in the subgroup with better glycemic control
and 1.50 (95% CI 0.43, 2.57) in the worse glycemic control subgroup. S1 Table shows the sub-
groups/sensitivity analyses respect to the number of participants to each study and to the NOS
score. The overall effect was more stable when studies included more than 45 subjects and the
NOS score was above 6.
None of the studies ranked between 1–3 NOS score, four studies (26%) were between 4–5
while the majority of studies were above 6 NOS score. Visual inspection of the funnel plot (Fig
4) did not identify substantial asymmetry and the Egger test for funnel plot asymmetry showed
a p value of 0.36.
Discussion
Our meta-analysis investigated the WMD of averaged E/e’ ratio between patients with type 2
diabetes without cardiovascular complications and non-diabetic controls. Care was taken in
selecting studies that clearly reported that included subjects were free of cardiovascular com-
plications, but non complicated hypertension.
We found a significantly higher averaged E/e’ ratio in patients with type 2 diabetes. These
findings may suggest the presence of LVDD in type 2 diabetes patients in the absence of signif-
icant cardiovascular complications and they were consistent either in subjects with and with-
out non complicated hypertension or good and bad glycemic control. Thus, the results of this
meta-analysis seems to indicate a possible direct detrimental effect of T2DM on the diastolic
performance of myocardium.
Diastolic alterations may be a precocious phenomenon of the diabetic heart: indicated as
diabetic cardiomyopathy [30].
Heart failure, especially HFpEF, and type 2 diabetes are frequently found associated in the
same patient [31–32]. The coexistence of the two diseases is associated with a more severe clin-
ical status and the prognosis is encumbered by an increased risk of all-cause and cardiovascu-
lar mortality [33]. We excluded subjects with cardiovascular diseases, that are responsible for
most of the case of HF in diabetes. The other main cause of HF is arterial hypertension, that in
our study was considered in the subgroups/sensitivity analyses. Therefore, after the exclusion
of the main causes, HF may be the consequence of T2DM related-processes [34]. Major mech-
anisms of myocardial alteration in T2DM are insulin resistance/hyperinsulinemia and pre-dia-
betic conditions, such as obesity, dysglycemia and others. Hyperinsulinemia and dysglycemia
may be present years or even decades before overt diabetes, likely contributing to myocardial
dysfunction during this period [35]. In fact, left ventricular diastolic dysfunction may be
detected in as many as about 75% of T2DM patients. Moreover, according to demographic
characteristics of these patients, that may include younger age, normal blood pressure and
E/e’ ratio in patients with diabetes vs controls
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optimal glycemic control, it can be supposed that left ventricular dysfunction may develop
early in the course of the disease [1, 36–37].
Numerous metabolic abnormalities, commonly found in diabetes, may be detrimental to
left ventricular diastolic function. Among these metabolic abnormalities are to be underlined
for their importance nonenzymatic glycation of proteins, lipotoxicity and microvascular rarefi-
cation: all these abnormalities eventually lead to apoptosis and fibrosis [34].
One simple clinical approach to detect myocardial dysfunction is transthoracic echocardi-
ography with TDI investigation. In particular, the E/e’ ratio, that estimates the left ventricular
filling pressure, is one of the most important parameters to detect diastolic dysfunction in sub-
jects with pEF. When E/e’ ratio increased at rest, it associates with adverse outcomes [38].
E/e’ ratio has been shown to possess a good prognostic impact on different outcomes such
as all-cause mortality, cardiovascular death and heart failure hospitalization in various studies
Fig 4. The Funnel plot analysis of the studies included in the analysis.
https://doi.org/10.1371/journal.pone.0209794.g004
E/e’ ratio in patients with diabetes vs controls
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[39–40]. Furthermore, a 4-year longitudinal study showed that progressive worsening in E/e’
ratio was associated with an increased incidence of heart failure [41]. We believed that the nov-
elty of our study are: the care of the selected patients thus proving that E/e’ may represent an
early alteration, and second that patients with normal blood pressure and higher level of
HbA1c showed a higher variability in the estimates. Therefore, even patients in good metabolic
control may develop alteration in E/e’ ratio and hypertension may contribute to this alteration.
The results of our meta-analysis are clinically relevant as they indicate that a single a reproduc-
ible parameter may be precociously altered. However, it should be remembered that we do not
have cutoff levels of averaged E/e’ under the value of 14. Future studies are needed to evaluate
the linear prognostic value of this parameter.
An advance in our knowledge is the routine measure of E/e’ ratio, as marker of increased
LV filling pressure, given the high prevalence of hypertension and heart failure in T2DM.
Screening HF is important since its two early phases, stage A (HF risk factors), and stage B
(characterized by structural or functional evidence of myocardial disease), are asymptomatic
[42]. It is of note that in these two HF stages T2DM is cited and therapy, with protective effect,
has an established indication in the prevention of incident HF. Thus, echocardiography is a
test that may potentially influence therapeutic decision making.
Sources of heterogeneity
In the present meta-analysis there was a substantial heterogeneity among the publications (I2
> 50%). Several factors might explain the heterogeneity, such as the characteristics of both dia-
betes and controls populations. Another possible factor of heterogeneity is the different echo-
cardiographic equipment in the diverse centers. Moreover, different factors, such as age,
glycemic control, hypertension may be associated with variations of E/e’ ratio, for this reason
we performed subgroups analyses to take into account these possible confounders. As shown
in Fig 2, region, glycemic control and hypertension can decrease the heterogeneity.
Study strengths and limitations
The major strength of this study is the comprehensiveness of the literature retrieval and review.
All studies included subjects with no cardiovascular diseases. We also included important clin-
ical factors such as glycemic control and hypertension. The data of the studies are as complete
as possible, and we included only case-control studies with a fair representation of recent pub-
lications. Moreover, we performed subgroups analyses to further illustrate the result of this
topic. And finally, as far as we know the present is the most comprehensive and updated syn-
thesis of E/e’ ratio in patients with type 2 diabetes.
This study has limitations. The matching between cases and controls was not consistent in
all studies. The inclusion and exclusion criteria slightly differed among studies. The clinical
characteristics of T2DM patients were not complete in some study. Diabetes duration was not
reported in many studies. Heterogeneity is substantial among studies even in the subgroup
analyses. Despite of all the limitations, the results of this analysis are consistent.
Conclusions
In conclusion, our assessment suggests that averaged E/e’ ratio is consistently increased in type
2 diabetes patients compared to non-diabetic controls in the absence of cardiovascular diseases
and complicated hypertension. This alteration may be a precocious diastolic alteration of the
diabetic cardiomyopathy. Nevertheless, the prognostic role of E/e’ should be considered with
caution. Future studies relating outcomes to E/e’ in diabetes may clarify the real prognostic
importance of this parameter.
E/e’ ratio in patients with diabetes vs controls
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